Prognostic tissue markers in melanoma

Histopathology

Volumn 60, Issue 5, 2012, Pages 679-689

  Moore, David A ^a   Pringle, J Howard ^a   Saldanha, Gerald S ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Biomarkers; Comparative genomic hybridization; Gene expression profiling; Immunohistochemistry; Melanoma; Polymerase chain reaction; Prognosis; Review; Translational research

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; BETA CATENIN; BREAST CANCER METASTASIS SUPPRESSOR 1 PROTEIN; CD146 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; KI 67 ANTIGEN; METALLOTHIONEIN I; METALLOTHIONEIN II; MICROPTHALMIA TRANSCRIPTION FACTOR; MICRORNA; NUCLEAR STEROID RECEPTOR COACTIVATOR A3; OSTEOPONTIN; PROTEIN; PROTEIN BCL 6; PROTEIN P16; PROTEIN P21; REGULATOR OF G PROTEIN SIGNALLING 1; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; WNT5A PROTEIN;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE SPECIFIC SURVIVAL; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; MELANOMA; MITOSIS; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; TISSUE MICROARRAY; WNT SIGNALING PATHWAY;

COMPARATIVE GENOMIC HYBRIDIZATION; GENE EXPRESSION PROFILING; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; POLYMERASE CHAIN REACTION; PROGNOSIS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860413726     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03910.x     Document Type: Review

References (52)

1. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 2009; 36; 6199-6206.
2. Slater DN, McKee PH. Minimum dataset for the histopathological reporting of common skin cancers. The Royal College of Pathologists, 2002. Available at: (accessed 20 March 2008).
3. Frishberg DP, Balch C, Balzer BL et al. Protocol for the examination of specimens from patients with melanoma of the skin. College of American Pathologists, 2011. Available at: (accessed 7 January 2011).
4. Kaur C, Thomas RJ, Desai N et al. The correlation of regression in primary melanoma with sentinel lymph node status. J. Clin. Pathol. 2008; 61; 297-300.
5. Gimotty PA, Guerry D, Ming ME et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J. Clin. Oncol. 2004; 22; 3668-3676.
6. Gould Rothberg BE, Bracken MB, Rimm DL. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J. Natl Cancer Inst. 2009; 101; 452-474.
7. Carlson JA, Ross JS, Slominski AJ et al. New techniques in dermatopathology that help to diagnose and prognosticate melanoma. Molecular diagnostics in melanoma. Clin. Dermatol. 2009; 27; 75-102.
8. Ladstein RG, Bachmann IM, Straume O, Akslen LA. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer 2010; 10; 140.
9. Gimotty PA, Van Belle P, Elder DE et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J. Clin. Oncol. 2005; 23; 8048-8056.
10. Frahm SO, Schubert C, Parwaresch R, Rudolph P. High proliferative activity may predict early metastasis of thin melanomas. Hum. Pathol. 2001; 32; 1376-1381.
11. Barry M, Sinha SK, Leader MB, Kay EW. Poor agreement in recognition of abnormal mitoses: requirement for standardized and robust definitions. Histopathology 2001; 38; 68-72.
12. Weinlich G, Bitterlich W, Mayr V, Fritsch PO, Zelger B. Metallothionein-overexpression as a prognostic factor for progression and survival in melanoma. A prospective study on 520 patients. Br. J. Dermatol. 2003; 149; 535-541.
13. Weinlich G, Eisendle K, Hassler E, Baltaci M, Fritsch PO, Zelger B. Metallothionein-overexpression as a highly significant prognostic factor in melanoma: a prospective study on 1270 patients. Br. J. Cancer 2006; 94; 835-841.
14. Salti GI, Manougian T, Farolan M, Shilkaitis A, Majumdar D, Das Gupta TK. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res. 2000; 60; 5012-5016.
15. Lewis TB, Robison JE, Bastien R et al. Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. Cancer 2005; 104; 678-686.
16. Kitago M, Koyanagi K, Nakamura T et al. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin. Chem. 2009; 55; 757-764.
17. Wang Y, Radfar S, Liu S, Riker AI, Khong HT. Mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-associated transcription factor-M, as a candidate biomarker for melanoma. BMC Med. 2010; 8; 14.
18. Samija I, Lukac J, Maric-Brozic J et al. Prognostic value of microphthalmia-associated transcription factor and tyrosinase as markers for circulating tumor cells detection in patients with melanoma. Melanoma Res. 2010; 20; 293-302.
19. Da Forno PD, Pringle JH, Hutchinson P et al. WNT5A expression increases during melanoma progression and correlates with outcome. Clin. Cancer Res. 2008; 14; 5825-5832.
20. Li J, Cheng Y, Tai D, Martinka M, Welch DR, Li G. Prognostic significance of BRMS1 expression in human melanoma and its role in tumor angiogenesis. Oncogene 2011; 30; 896-906.
21. Pearl RA, Pacifico MD, Richman PI, Wilson GD, Grover R. Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: implications for sentinel lymph node biopsy. J. Plast. Reconstr. Aesthet. Surg. 2008; 61; 265-271.
22. Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD. Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker. Plast. Reconstr. Surg. 2005; 115; 367-375.
23. Lin H, Wong RP, Martinka M, Li G. Loss of SNF5 expression correlates with poor patient survival in melanoma. Clin. Cancer Res. 2009; 15; 6404-6411.
24. Alonso SR, Ortiz P, Pollan M et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am. J. Pathol. 2004; 164; 193-203.
25. Kashani-Sabet M, Venna S, Nosrati M et al. A multimarker prognostic assay for primary cutaneous melanoma. Clin. Cancer Res. 2009; 15; 6987-6992.
26. Gould Rothberg BE, Berger AJ, Molinaro AM et al. Melanoma prognostic model using tissue microarrays and genetic algorithms. J. Clin. Oncol. 2009; 27; 5772-5780.
27. Mian S, Ugurel S, Parkinson E et al. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J. Clin. Oncol. 2005; 23; 5088-5093.
28. Findeisen P, Zapatka M, Peccerella T et al. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J. Clin. Oncol. 2009; 27; 2199-2208.
29. Sabatino M, Kim-Schulze S, Panelli MC et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J. Clin. Oncol. 2009; 27; 2645-2652.
30. Berg D, Hipp S, Malinowsky K, Böllner C, Becker KF. Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissues. Eur. J. Cancer 2010; 46; 47-55.
31. Nirmalan NJ, Harnden P, Selby PJ, Banks RE. Development and validation of a novel protein extraction methodology for quantitation of protein expression in formalin-fixed paraffin-embedded tissues using Western blotting. J. Pathol. 2009; 217; 497-506.
32. Winnepenninckx V, Lazar V, Michiels S et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J. Natl Cancer Inst. 2006; 98; 472-482.
33. Haqq C, Nosrati M, Sudilovsky D et al. The gene expression signatures of melanoma progression. Proc. Natl Acad. Sci. USA 2005; 102; 6092-6097.
34. Conway C, Mitra A, Jewell R et al. Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin. Cancer Res. 2009; 15; 6939-6946.
35. Segura MF, Belitskaya-Levy I, Rose AE et al. Melanoma MicroRNA signature predicts post-recurrence survival. Clin. Cancer Res. 2010; 16; 1577-1586.
36. Satzger I, Mattern A, Kuettler U et al. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int. J. Cancer 2010; 126; 2553-2562.
37. Siebolts U, Varnholt H, Drebber U, Dienes HP, Wickenhauser C, Odenthal M. Tissues from routine pathology archives are suitable for microRNA analyses by quantitative PCR. J. Clin. Pathol. 2009; 62; 84-88.
38. Jönsson G, Busch C, Knappskog S et al. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin. Cancer Res. 2010; 16; 3356-3367.
39. Grafstrom E, Egyhazi S, Ringborg U, Hansson J, Platz A. Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival. Clin. Cancer Res. 2005; 11; 2991-2997.
40. Conway C, Beswick S, Elliott F et al. Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma. Genes Chromosom. Cancer 2010; 49; 425-438.
41. Akslen LA, Angelini S, Straume O et al. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J. Invest. Dermatol. 2005; 125; 312-317.
42. Shinozaki M, Fujimoto A, Morton DL, Hoon DS. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin. Cancer Res. 2004; 10; 1753-1757.
43. Ugurel S, Thirumaran RK, Bloethner S et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS ONE 2007; 2; e236.
44. Kumar R, Angelini S, Snellman E, Hemminki K. BRAF mutations are common somatic events in melanocytic nevi. J. Invest. Dermatol. 2004; 122; 342-348.
45. Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. Br. J. Cancer 2011; 104; 392-398.
46. Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. J. Clin. Epidemiol. 2007; 60; 1205-1219.
47. Sackett DL, Haynes RB. The architecture of diagnostic research. BMJ 2002; 324; 539-541.
48. Pepe MS, Etzioni R, Feng Z et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 2001; 93; 1054-1061.
49. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J. Natl Cancer Inst. 2005; 97; 1180-1184.
50. Dupuy A, Simon RM. Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J. Natl Cancer Inst. 2007; 99; 147-157.
51. Pepe MS, Feng Z, Janes H, Bossuyt PM, Potter JD. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J. Natl Cancer Inst. 2008; 100; 1432-1438.
52. Harbour JW. Molecular prognostic testing and individualized patient care in uveal melanoma. Am. J. Ophthalmol. 2009; 148; 823-829.